1-4 of 4
Jeffrey Settleman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PR09: Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS-mutant cancer models

Ryan B. Corcoran, Katherine A. Cheng, Aaron N. Hata, Anthony C. Faber, Hiromichi Ebi, Erin M. Coffee, Patricia Greninger, Ronald D. Brown, Jason T. Godfrey, Travis J. Cohoon, Youngchul Song, Eugene Lifshits, Toshi Shioda, Dora Dias-Santagata, Anurag Singh, Jeffrey Settleman, Cyril H. Benes, Mari Mino-Kenudson, Kwok-Kin Wong, Jeffrey A. Engelman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (5_Supplement): PR09.
https://doi.org/10.1158/1535-7163.PMS-PR09
Published: 01 May 2014
View article titled, Abstract PR09: Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS-mutant cancer models
Journal Articles

Abstract C137: Rapid assessment of TORC1 suppression as a functional biomarker predicting responsiveness to RAF and MEK inhibitors in BRAF-mutant melanoma patients.

Ryan B. Corcoran, S. Michael Rothenberg, Aaron N. Hata, Anthony C. Faber, Adriano Piris, Rosalynn M. Nazarian, Ronald D. Brown, Jason T. Godfrey, Daniel Winokur, John Walsh, Mari Mino-Kenudson, Shyamala Maheswaran, Jeffrey Settleman, Jennifer A. Wargo, Keith T. Flaherty, Daniel A. Haber, Jeffrey A. Engelman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C137.
https://doi.org/10.1158/1535-7163.TARG-13-C137
Published: 01 November 2013
View article titled, Abstract C137: Rapid assessment of TORC1 suppression as a functional biomarker predicting responsiveness to RAF and MEK inhibitors in BRAF-mutant melanoma patients.
Journal Articles

Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models

Nguyen Tan, Maureen Wong, Michelle A. Nannini, Rebecca Hong, Leslie B. Lee, Stephen Price, Karen Williams, Pierre Pascal Savy, Peng Yue, Deepak Sampath, Jeffrey Settleman, Wayne J. Fairbrother, Lisa D. Belmont
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2013) 12 (6): 853–864.
https://doi.org/10.1158/1535-7163.MCT-12-0949
Published: 09 June 2013
View article titled, Bcl-2/Bcl-x<sub>L</sub> Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models
Open the PDF for Bcl-2/Bcl-x<sub>L</sub> Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models in another window
Includes: Supplementary data
Journal Articles

The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor

Nadia Godin-Heymann, Lindsey Ulkus, Brian W. Brannigan, Ultan McDermott, Jennifer Lamb, Shyamala Maheswaran, Jeffrey Settleman, Daniel A. Haber
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (4): 874–879.
https://doi.org/10.1158/1535-7163.MCT-07-2387
Published: 15 April 2008
View article titled, The T790M “gatekeeper” mutation in <em>EGFR</em> mediates resistance to low concentrations of an irreversible EGFR inhibitor
Open the PDF for The T790M “gatekeeper” mutation in <em>EGFR</em> mediates resistance to low concentrations of an irreversible EGFR inhibitor in another window